Retrophin Names Margaret Valeur-Jensen, Ph.D. as General Counsel

Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Margaret Valeur-Jensen, Ph.D. to the newly created position of General Counsel, effective immediately. She will be responsible for providing legal advice regarding the Company’s commercial operations, research activities, business development and compliance with industry standards.

Dr. Valeur-Jensen joins Retrophin from Seed Intellectual Property Law Group PLLC. There, she served as Of Counsel in the Biotechnology, Pharmaceuticals and Chemistry Group. Previously, she was Executive Vice President and General Counsel of Neurocrine Biosciences, Inc., where she was responsible for all patent and corporate practice including management of patent portfolio and strategy, corporate partnering, regulatory compliance, and public company issues. Earlier, she was Associate General Counsel Business Law Group of Amgen Inc., where she was responsible for licensing and corporate partnering, mergers and acquisitions, clinical development, sales and marketing, regulatory affairs, and real estate. Prior to joining Amgen, she was an associate at Davis, Polk & Wardwell.

“The addition of Meg as General Counsel strengthens our management team,” said Stephen Aselage, Chief Executive Officer of Retrophin. “Her deep legal expertise as it relates to the biopharmaceutical industry will be vital as we enter the next phase of our transition and accelerate the Company’s growth.”

“I’m delighted to join Retrophin at such an exciting time,” said Dr. Valeur-Jensen. “I look forward to working with the team to ensure compliance as it maximizes commercial products, advances key pipeline assets, and pursues business development opportunities.”

Dr. Valeur-Jensen received her J.D. from Stanford University School of Law. In addition, she was a Post-Doctoral Fellow at Harvard Medical School in the Department of Genetics, as well as at Massachusetts General Hospital in the Department of Molecular Biology. She received a Ph.D. in Biochemistry and Molecular Biology from Syracuse University and a B.A. in Biology from Skidmore College.

Retrophin also announced the grant of an inducement award to Ms. Valeur-Jensen pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules in connection with her employment with Retrophin. In connection with her employment, Ms. Valeur-Jensen was granted an inducement award consisting of 100,000 shares of restricted common stock, which will vest in full on November 1, 2015. The restricted common stock award is subject to the terms and conditions of Retrophin’s 2014 Incentive Compensation Plan. The award was granted as an inducement material to Ms. Valeur-Jensen’s employment pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

About Retrophin

Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal®, Thiola® and Vecamyl®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis (FSGS), pantothenate kinase-associated neurodegeneration (PKAN), schizophrenia, infantile spasms, nephrotic syndrome and others. For additional information, please visit www.retrophin.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Without limiting the foregoing, these statements are often identified by the words "may", "might", "believes", "thinks", "anticipates", "plans", "expects", "intends" or similar expressions. No forward-looking statement can be guaranteed. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. The Company undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties as included in the Company's filings with the Securities and Exchange Commission.